Abstract: A method of treating or alleviating symptoms of a disorder or a condition in a subject, including identifying the disorder or the condition of a subject, the disorder or condition identified based on first measures of a bloodstream concentration of a substance or a blood stream count of cellular elements, orally administering to said subject an amount of cannabidiol over a period of time effective treat or alleviate symptoms of said disorder or said condition, altering the bloodstream concentration of said substance or said blood stream count of cellular elements, and assessing efficacy of treating or alleviating symptoms of the disorder or the condition evidenced by comparing second measures of the bloodstream concentration of the substance or the blood stream count of cellular elements after the period time to the first measures of bloodstream concentration of the substance or the blood stream count of cellular elements.

Abstract: A topical composition and method of treating chronic pain are provided. The topical composition contains cannabidiol (CBD) and plant extract and is well suited to treat chronic pain while also avoiding the negative side effects caused by commonly used anti-inflammatory and pain-treating compounds. When the topical composition is applied to the skin at the locus of pain and allowed sufficient time to absorb, the pain is reduced or even eliminated. The topical compositions also show therapeutic effect on mucosal tissue and internal tissues of humans or animals.

Abstract: The present disclosure relates to compositions, methods of use and methods of manufacturing of a transdermal delivery systems, patches, vehicles and devices used to relieve pain (i.e., analgesics) and/or inflammation that contain a pharmaceutically effective amount of a pharmaceutically acceptable and effective cannabinoid and menthol.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The invention includes the use of cannabidiol (CBD), and cannabidiol analogs, as therapeutic compounds or formulations for the increase of lipid order in the cell membranes of a patient. This increase in membrane lipid order may cause downstream therapeutic effects that may ameliorate certain disease conditions such as cardio vascular disease, high-cholesterol and Alzheimer's disease.

Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula TT, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.

Abstract: A pharmaceutical composition is described. The composition comprises; (i) a drug component comprising salbutamol; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

Abstract: A method of treating postprandial inflammation may include administering to a subject an edible composition comprising the ACSL1 inhibitor within hours of the subject consuming a food. The edible composition may be administered by consumption by the subject at the same time as the subject consumes the food. The food may be high in saturated fatty acids.

Abstract: A ketogenic R-beta-hydroxybutyrate mixed salt-acid composition includes enantiomerically pure R-beta-hydroxybutyric acid and one or more enantiomerically pure R-beta-hydroxybutyrate salts. The R-beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. The enantiomerically pure R-beta-hydroxybutyrate salt(s) are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and an R-beta-hydroxybutyrate mixed salt-acid composition. The composition contains less than 100% by molar equivalents of total enantiomerically pure R-beta-hydroxybutyrate salts and more than 0% by molar equivalents of enantiomerically pure R-beta-hydroxybutyric acid.

Abstract: The present invention pertains to novel uses of glycyrrhetinic acid (GA), glycyrrhizic acid (GR) and related compounds for mitigation and/or treatment of pneumonitis/pneumonia/pulmonary fibrosis induced by various chemicals/bioagents and/or pathogens, such as anti-cancer therapies and/or virus. Also embodied are therapeutic uses of prodrugs, metabolites, derivatives (e.g., acids, esters and ethers), and salts of glycyrrhetinic acid (GA) and glycyrrhizic acid (GR) in a form of drugs, health products, foods or food additives.

Abstract: The present invention relates to methods for treating or preventing or delaying the progression or onset of autoimmune disease, comprising the use of dietary metabolites.

Abstract: Systems and methods for treating a fibrous mass associated with a condition such as Morton's neuroma, plantar firbroma, or Achilles tendinopathy are disclosed. According to illustrative implementations, exemplary methods may comprise identifying a location of the fibrous mass and non-surgically delivering electromagnetic energy to the fibrous mass.

Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.

Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.

Abstract: Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

Abstract: The present invention relates to the compositions, formulations and methods of treating fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and their sequelae by administration of 15-OHEPA.

Abstract: The subject invention relates to novel methods for the rapid treatment of disorders resulting from thrombosis or embolism such as a myocardial infraction or stroke. Specifically, the invention relates to diffusion enhancing compounds and their use with embolectomy and thrombectomy, or other procedures for the treatment of ischemia.

Abstract: The present invention relates to a treatment of vaso-occlusive crisis (VOC) associated with Sickle cell disease by administering a therapeutically effective amount of 4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate.

Abstract: The present invention relates to methods of reducing ischemic damage to a surgical incision in a tissue of subject, enhancing tissue viability and vascularity following an ischemic event, and preconditioning tissue to resist an ischemic insult, which comprises contacting the relevant tissue topically with an effective dose of a HIF-1 potentiating agent, thereby reducing ischemic damage to a surgical incision, enhancing tissue viability and vascularity following an ischemic event, and preconditioning tissue to resist an ischemic insult.

Abstract: A method for treating an infectious disease, including the step of administering an isothiocyanate functional surfactant to a patient having an infectious disease.

Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.

Abstract: The present disclosure relates to the field of combination therapy for treatment of hematological malignancy selected from myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosure provides a combination therapy comprising plant based compounds and hypomethylating agent (HMA). Particularly, the disclosure provides a combination of: a) a therapeutically effective amount of a combination comprising sulforaphane, resveratrol and curcumin; and b) a therapeutically effective amount of HMA selected from azacitidine (AZA), decitabine (DEC) and a combination thereof, for treating MDS or AML. Said combination provides an enhanced/synergistic effect in the treatment of MDS or AML along with decreasing or overcoming resistance to HMA (azacitidine or decitabine). Methods for decreasing or overcoming resistance to HMA (azacitidine or decitabine), corresponding use of the above described combination and a kit comprising said combination are also provided.

Abstract: Provided herein are methods of using cabazitaxel in mCRPC patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent.

Abstract: In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided.

Abstract: The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

Abstract: This invention provides a composition for external use comprising an ascorbic acid compound. More preferably, provided is an ascorbic acid compound-containing composition for external use in which precipitation under a low-temperature storage condition is suppressed. The composition for external use comprises the following components: (A) at least one member selected from the group consisting of ascorbic acid, derivatives thereof, and salts thereof; (B) an edetic acid salt; (C) a glycyrrhizic acid salt; (D) a heparinoid; and (E) water.

Abstract: The present application relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disease or disorder, for example multiple sclerosis (MS).

Abstract: This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment.

Abstract: The present disclosure relates generally to pharmaceutical formulations of oxymetazoline and, more specifically, formulations of oxymetazoline containing one or more transition metal additives and having enhanced stability against degradation.

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Abstract: The present disclosure relates to methods of treating cancer comprising administering Parkin ligase activator or a pharmaceutically acceptable salt thereof to a subject who has a mutant form of a protein in the Rb checkpoint pathway. The Parkin ligase activator includes triazole compounds, such as compounds of formula (I), and pharmaceutically acceptable salts thereof as disclosed herein. R1, R2, R3, M1, M2, M3, L1, L2, and L3 are as defined herein.

Abstract: Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition in a subject with a GPX4 inhibitor and an anticancer agent. Also provided herein are methods of inducing ferroptosis in a cell or inhibiting the growth of a cell with a GPX4 inhibitor and an anticancer agent.

Abstract: The present invention provides N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide known as vemurafenib, and pharmaceutical salts thereof for use in the treatment of enteroviral diseases.

Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes.

Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.

Abstract: Compositions comprising a mixture of at least two types of particles wherein a) the first type of particles comprise dabigatran etexilate in the form of the free base or in the form of pharmaceutically acceptable salts, polymorphs, solvates or hydrates thereof; and b) the second type of particles comprise at least one pharmaceutically acceptable organic acid, use of said compositions in the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation and/or in the prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery and processes for the preparation of said compositions.

Abstract: This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: A pharmaceutical composition contains apomorphine as the active pharmaceutical ingredient, a water-miscible co-solvent, an antioxidant, and water. The solution has a pH greater than 4. The pharmaceutical composition is suitable for parenteral administration for the treatment of Parkinson's disease. The process for the manufacture of the pharmaceutical composition includes weighing the apomorphine and introducing it into a container with the co-solvent and the antioxidant under agitation until complete dissolution takes place.

Abstract: Described herein are methods and systems for using an alkaloid, such as manzamine A, for anti-proliferative effects at relatively low and non-cytotoxic concentrations (up to 4 ?M) wherein manzamine A blocks cell cycle progression in cervical cancer cell lines and regulates cell cycle-related genes, including restoration of p21 and p53 expression inducing apoptosis.

Abstract: In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol or powder formulations for inhalation are provided.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: Compositions and methods for treating or preventing peripheral neuropathy in a subject determined to be in need thereof. The method comprises a step of topically administering to the subject anti-peripheral neuropathic compounds acting as GFR a 3 type receptor agonist.

Abstract: The present disclosure relates to solid state forms of Selinexor, processes for preparation thereof and pharmaceutical compositions thereof.

Abstract: An object of the present invention is to provide a pharmaceutical composition containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide which is rapidly dissolved in a weakly acidic test solution. According to the present invention, a pharmaceutical composition containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide and at least one or more kinds selected from the group consisting of celluloses, sugars, and sugar alcohol is provided.

Abstract: An object of the present invention is to provide a tablet containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino) -N-methylbut-2-enamide (Compound A) which is rapidly dissolved in a weakly acidic solution in order to prevent a decrease in bioavailability. According to the present invention, there is provided a tablet containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino) -N-methylbut-2-enamide (Compound A), at least one or more kinds selected from the group consisting of sugars and sugar alcohol, and crospovidone.